[Clinical and psychological features of people with internet dependence: experience of a pilot study]. / Kliniko-psikhopatologicheskie osobennosti lits s internet-zavisimost'yu: opyt pilotnogo issledovaniya.

OBJECTIVE: The prevalence of Internet addiction (IA) is growing steadily, especially among the younger generation. The purpose of this multicenter study was to investigate the socio-demographic characteristics, clinical varieties, and profile of psychopathological symptoms of mental disorders in patients with IA. MATERIAL AND METHODS: The study included 2 groups: the main group consisted of 44 people, aged 16 to 34 years, average age 22.00±0.66 years, 33 (75%) men, 11 (25%) women; the control group included 120 people, aged 19 to 30 years, average age 23.13±0.18 years, 90 (74.3%) men, 30 (26.7%) women. Groups were identified at the testing stage based on the total score on the Chen Internet Addiction Scale (CIAS). The main group included individuals who scored CIAS 65 points or higher. The specially developed Unified Study Card, The Mini international neuropsychiatric interview (MINI), the Hospital Anxiety and Depression Scale (HADS), the Beck Depression Questionnaire (BDI), the Prodromal Questionnaire-16 (PQ-16), the Symptom Checklist-90-Questionnaire Revised (SCL-90-R). RESULTS AND CONCLUSION: There were more people with secondary specialized education and unemployed in the main group. The family burden of addiction and psychiatric disorders did not differ in both groups, and the heredity of somatic diseases was lower in the IA group. In the IA group, a psychiatric diagnosis was made 9 times more often. The severity of affective and anxiety disorders was higher in the IA group, while the risk of psychosis was low that allows considering the symptoms of IA outside the framework of subpsychotic mental disorders. The features of the psychopathological symptoms of IA were: total «tension¼ of the psychopathological profile; a relatively uniform and slightly specific profile of psychopathological symptoms with a certain tendency to the prevalence of personality-related stress manifestations.

[Multikinase inhibitor sorafenib and HDAC inhibitor suberoylanilide hydroxamic acid suppress confluent resistance of cancer cells to recombinant protein izTRAIL].

Suppression of human tumor cell resistance to TRAIL-induced apoptosis in confluent cultures, using molecular target drugs (sorafenib and SAHA) at non-toxic concentrations was studied. Sorafenib, a multikinase inhibitor, and SAHA, an inhibitor of histone deacetylase, effectively suppressed resistance of confluent human cells derived from the skin carcinoma (A431 cell line) and fibrosarcoma (HT-1080 cell line). The effectiveness of suppression of confluent resistance with these inhibitors for human carcinoma A431 cells was significantly higher than that for the human ovarian carcinoma OVCAR-3 cells. For all cell lines studied, suppression of confluent resistance with SAHA was more effective than when sorafenib was used. The possible reason for increasing tumor cell resistance in confluent cultures and the importance of this phenomenon for understanding drug resistance of cells in the tumor tissue are discussed.

[Increase in resistance of A431 cancer cells to TRAIL-induced apoptosis in confluent cultures].

It was shown that cancer cells acquired resistance to TRAIL-induced apoptosis in confluent cultures. Recombinant protein izTRAIL induced apoptosis of human carcinoma A431 cells in the first hours after cell plating at a concentration of 3-10 ng/ml, while in confluent cultures these cells acquire resistance to protein izTRAIL even at the concentration of 2 mkg/ml. Detachment and suspending of the cells of confluent cultures immediately suppressed the resistance to izTRAIL. The cells of confluent cultures, being resistant to TRAIL-induced apoptosis continue progression through the cell cycle, as evidenced by the DNA cytograms and the Ki67p-GFP reporter system. Thus, the results showed that tumor A431 cells can acquire resistance to TRAIL-induced apoptosis in confluent cultures, while continue progression through the cell cycle, keeping the proliferative potential.